PMID- 34384339
OWN - NLM
STAT- MEDLINE
DCOM- 20210830
LR  - 20220425
IS  - 1607-8454 (Electronic)
IS  - 1024-5332 (Linking)
VI  - 26
IP  - 1
DP  - 2021 Dec
TI  - Efficacy and safety of cladribine addition to induction treatment of newly 
      diagnosed acute myeloid leukemia: a systematic review and meta-analysis.
PG  - 577-587
LID - 10.1080/16078454.2021.1962047 [doi]
AB  - OBJECTIVES: Compared with the 3 + 7 regimen, the cladribine-containing regimen 
      has led to improvements in the rate of complete remission (CR) in the treatment 
      of newly diagnosed acute myeloid leukemia (AML) patients. We conducted a 
      systematic review and meta-analysis to investigate the overall efficacy and 
      safety of cladribine-containing regimens in the induction treatment of newly 
      diagnosed AML patients. METHODS: Eligible studies were identified from the 
      PubMed, EMBASE, and Cochrane Library databases. Efficacy was assessed by CR rate, 
      disease-free survival (DFS), and overall survival (OS). Safety was evaluated 
      based on the early death (ED) rate, days for neutrophils<0.5 x 10(9)/L, days for 
      platelets<50 x 10(9)/L, and duration of hospital stay after treatment. RESULTS: A 
      total of 14 clinical trials were included in this meta-analysis, enrolling a 
      total of 1058 newly diagnosed AML patients. The pooled estimate with a 95% 
      confidence interval (CI) for CR was 64% (95% CI: 58-70%). Compared with the 
      control group, the CR rate of the cladribine-containing regimen was higher (OR 
      was 1.92 (95% CI: 1.55-2.38)). The combined ED rate was estimated to be 10% (95% 
      CI: 5-14%). Compared with the control group, the ED rate of the 
      cladribine-containing regimen was not increased (OR was 1.09 (95% CI: 
      0.78-1.53)). CONCLUSION: This meta-analysis suggests that cladribine-containing 
      regimens are likely to be effective and safe for induction treatment of newly 
      diagnosed AML patients. However, large sample size and prospective controlled 
      studies are needed to confirm our findings.
FAU - Pan, Qianying
AU  - Pan Q
AUID- ORCID: 0000-0002-9804-3441
AD  - Department of Hematology, The First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, People's Republic of China.
FAU - Li, Juan
AU  - Li J
AUID- ORCID: 0000-0002-0909-4731
AD  - Department of Hematology, The First Affiliated Hospital of Sun Yat-sen 
      University, Guangzhou, People's Republic of China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - England
TA  - Hematology
JT  - Hematology (Amsterdam, Netherlands)
JID - 9708388
RN  - 0 (Antineoplastic Agents)
RN  - 47M74X9YT5 (Cladribine)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Cladribine/adverse effects/*therapeutic use
MH  - Humans
MH  - Induction Chemotherapy
MH  - Leukemia, Myeloid, Acute/diagnosis/*drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cladribine
OT  - acute myeloid leukemia
OT  - induction treatment
OT  - meta-analysis
EDAT- 2021/08/14 06:00
MHDA- 2021/08/31 06:00
CRDT- 2021/08/13 05:35
PHST- 2021/08/13 05:35 [entrez]
PHST- 2021/08/14 06:00 [pubmed]
PHST- 2021/08/31 06:00 [medline]
AID - 10.1080/16078454.2021.1962047 [doi]
PST - ppublish
SO  - Hematology. 2021 Dec;26(1):577-587. doi: 10.1080/16078454.2021.1962047.